Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort


Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort


Adland, E.,Jesuthasan, G.,Downs, L.,Wharton, V.,Wilde, G.,McNaughton, A. L.,Collier, J.,Barnes, E.,Klenerman, P.,Andersson, M.,Jeffery, K.,Matthews, P. C.

BMC Infectious Diseases


Retrospective cohort
Virus targets
Hepatitis C
HCV testing and linkage to Care
Target populations
Country of development
United Kingdom
Target location
United Kingdom
Testing strategy
Laboratory-based antibody test
Laboratory-based HCV core antigen (cAg) confirmatory test
Laboratory-based PCR/RNA (confirmatory) test
Laboratory-based antibody test,Laboratory-based HCV core antigen (cAg) confirmatory test
Laboratory-based antibody test,Laboratory-based PCR/RNA (confirmatory) test

Health outcomes

Number new diagnoses, Linkage to care, Diagnostic test accuracy information

Testing algorithm

Laboratory-based antibody test,Laboratory-based PCR/RNA (confirmatory) test,Laboratory-based HCV core antigen (cAg) confimatory test



As direct acting antiviral (DAA) therapy is progressively rolled out for patients with hepatitis C virus (HCV) infection, careful scrutiny of HCV epidemiology, diagnostic testing, and access to care is crucial to underpin improvements in delivery of treatment, with the ultimate goal of elimination.


We retrospectively studied microbiology records from a large UK teaching hospital in order to compare the performance of HCV screening and diagnostic tests (antibody, antigen and HCV RNA detection). Having described a local cohort of adults with active HCV infection, we investigated the proportion who attended hospital appointments, were prescribed direct acting antiviral (DAA) therapy, and cleared HCV RNA following treatment.


Over a total time period of 33 months between 2013 and 2016, we tested 38,509 individuals for HCV infection and confirmed a new diagnosis of active HCV infection (HCV-Ag + and/or HCV RNA+) in 353 (positive rate 0.9%). Our in-house HCV-Ab screening test had a positive predictive value of 87% compared to repeat HCV-Ab testing in a reference laboratory, highlighting the potential for false positives to arise using this test. HCV-Ag had 100% positive predictive value compared to detection of HCV RNA. There was a strong correlation between quantitative HCV-Ag and HCV RNA viral load (p < 0.0001). Among the cases of infection, genotype-1 and genotype-3 predominated, the median age was 37 years, 84% were male, and 36% were in prison. Hepatology review was provided in 39%, and 22% received treatment. Among those who received DAA therapy with 12 weeks of follow-up, 93% achieved a sustained virologic response (SVR<inf>12</inf>).


HCV-Ag performs well as a diagnostic test compared to PCR for HCV RNA. Active HCV infection is over-represented among men and in the prison population. DAA therapy is successful in those who receive it, but a minority of patients with a diagnosis of HCV infection access clinical care. Enhanced efforts are required to provide linkage to clinical care within high risk populations.

Page updated

22 Jan 2021